Carisma Therapeutics Inc.
CARMDelisted Dec 15, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001485003
Carisma Therapeutics Inc. was delisted on Dec 15, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 33 institutions reported holding it in 13F filings for Q3 2025, worth $842.6K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 33
- Q3 2025, −3 vs. previous quarter
- 13F value
- $842.6K
- Reported value at the end of Q3 2025
- Superinvestors holding
- 0
- At the end of Q3 2025
Superinvestors holding CARM, Q3 2025
No superinvestor reported holding CARM at the end of Q3 2025.
Latest insider trades
Open-market purchases and sales by Carisma Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2025 (view filing)4:16 PM ET | Oct 7 | 1 day | Klichinsky MichaelChief Scientific Officer | SSale | −57.0K | $0.2542 | −$14.5K | −100.0%0 after | |
| Oct 3, 2025 (view filing)5:25 PM ET | Oct 1-3 | 2 days | Klichinsky MichaelChief Scientific Officer | SSale | −484.3K | $0.2567 | −$124.3K | −100.0%0 after | 3 lots |
| Mar 6, 2023 (view filing) | Mar 2 | 4 days | Sullivan MarkGeneral Counsel & Secretary | SSale | −219.2K | $0.59 | −$129.3K | −36.7%378.7K after | 3 lots |
| Mar 6, 2023 (view filing) | Mar 2 | 4 days | MacDonald Glen CChief Technology Officer | SSale | −170.4K | $0.59 | −$100.5K | −29.9%398.9K after | 3 lots |
| Mar 6, 2023 (view filing) | Mar 2 | 4 days | Ryu EllyPrincipal Accounting Officer | SSale | −17.3K | $0.59 | −$10.2K | −10.4%148.6K after | |
| Mar 6, 2023 (view filing) | Mar 2 | 4 days | Cannell Thomas RPresident and CEO | SSale | −487.5K | $0.59 | −$287.6K | −42.0%672.4K after | 2 lots |
| Mar 6, 2023 (view filing) | Mar 2 | 4 days | Forbes MonicaChief Financial Officer | SSale | −345.8K | $0.59 | −$204.1K | −40.6%505.7K after | 3 lots |
| Feb 23, 2023 (view filing) | Feb 21 | 2 days | Sullivan MarkGeneral Counsel & Secretary | SSale | −39.8K | $0.59 | −$23.5K | −11.7%299.7K after | |
| Feb 23, 2023 (view filing) | Feb 21 | 2 days | Ryu EllyPrincipal Accounting Officer | SSale | −7.16K | $0.59 | −$4.22K | −4.1%165.9K after | |
| Feb 23, 2023 (view filing) | Feb 21 | 2 days | Cannell Thomas RPresident and CEO | SSale | −53.7K | $0.59 | −$31.7K | −8.9%553.1K after |
Top 10 13F holders, Q3 2025
The largest institutional positions in Carisma Therapeutics Inc. at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Merck & Co., Inc. | 1,473,240 | $403.7K | 0.18% | 00.0% | Unchanged |
| Vanguard Group Inc | 350,324 | $96.0K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 336,789 | $92.3K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 293,686 | $80.5K | 0.00% | −35,600−10.8% | Reduced |
| Geode Capital Management, LLC | 250,495 | $68.7K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 85,106 | $23.3K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 55,039 | $15.1K | 0.00% | 00.0% | Unchanged |
| GTS Securities LLC | 50,118 | $13.7K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 30,988 | $8.49K | 0.00% | 00.0% | Unchanged |
| Empowered Funds, LLC | 30,988 | $8.49K | 0.00% | 00.0% | Unchanged |